Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Dimitris Repantis

Biographic Data

ID7954379
NAMEDimitris Repantis
GIVEN NAMESDimitris
FAMILY NAMERepantis
SIGNATUREREPANTIS D
AFFILIATIONSCharité - Universitätsmedizin Berlin
ORCID0000-0001-5130-6286
VERIFIEDYes
TOTAL WORKS4
TOTAL CITATIONS0
WORKS AS AUTHOR4
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2021
LATEST PUBLICATION YEAR2022
H-INDEX0
  • Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

    Open Access•Guy M Goodwin, Scott T Aaronson et al.•ARTICLE•New England Journal of Medicine•2022

    BACKGROUND: Psilocybin is being studied for use in treatment-resistant depression. METHODS: In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the total score on the Montgomery-Å…

  • Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder

    Open Access•Tor-Morten Kvam, Ivar W Goksøyr et al.•ARTICLE•Frontiers in Psychiatry•2022

    EudraCT number 2021-000805-26

  • A Central Clearing Clinic to Provide Mental Health Services for Refugees in Germany

    Open Access•Malek Bajbouj, Patricia Panneck et al.•ARTICLE•Frontiers in Public Health•2021

    Objective: To determine migration related distress pattern in refugees and feasibility of a de novo established, central low-threshold outpatient clinic serving more than 80,000 newly arrived refugees in the metropole of Berlin. Methods: In an observational cohort study the relative prevalence of major psychiatric disorders by age, place of living within berlin, language and region of origin were assessed in a refugee cohort from 63 nationalities…

  • Moral Psychopharmacology Needs Moral Inquiry

    Open Access•N Langlitz, Erika Dyck et al.•ARTICLE•Frontiers in Psychiatry•2021

    The revival of psychedelic research coincided and more recently conjoined with psychopharmacological research on how drugs affect moral judgments and behaviors. This article makes the case for a moral psychopharmacology of psychedelics that examines whether psychedelics serve as non-specific amplifiers that enable subjects to (re-)connect with their values, or whether they promote specific moral-political orientations such as liberal and anti-aut…

No prominent works on this page.

  • A Central Clearing Clinic to Provide Mental Health Services for Refugees in Germany

    Open Access•Malek Bajbouj, Patricia Panneck et al.•ARTICLE•Frontiers in Public Health•2021

    Objective: To determine migration related distress pattern in refugees and feasibility of a de novo established, central low-threshold outpatient clinic serving more than 80,000 newly arrived refugees in the metropole of Berlin. Methods: In an observational cohort study the relative prevalence of major psychiatric disorders by age, place of living within berlin, language and region of origin were assessed in a refugee cohort from 63 nationalities…

  • Moral Psychopharmacology Needs Moral Inquiry

    Open Access•N Langlitz, Erika Dyck et al.•ARTICLE•Frontiers in Psychiatry•2021

    The revival of psychedelic research coincided and more recently conjoined with psychopharmacological research on how drugs affect moral judgments and behaviors. This article makes the case for a moral psychopharmacology of psychedelics that examines whether psychedelics serve as non-specific amplifiers that enable subjects to (re-)connect with their values, or whether they promote specific moral-political orientations such as liberal and anti-aut…

  • Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

    Open Access•Guy M Goodwin, Scott T Aaronson et al.•ARTICLE•New England Journal of Medicine•2022

    BACKGROUND: Psilocybin is being studied for use in treatment-resistant depression. METHODS: In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the total score on the Montgomery-Å…

  • Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder

    Open Access•Tor-Morten Kvam, Ivar W Goksøyr et al.•ARTICLE•Frontiers in Psychiatry•2022

    EudraCT number 2021-000805-26

Medicine (3 works) · Psychedelics and Drug Studies (3 works) · Psychiatry (3 works) · Psychology (3 works) · Anxiety (2 works) · Sociology (2 works) · Adjustment disorders (1 work) · Adverse effect (1 work) · Alternative medicine (1 work) · Antidepressant (1 work)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae